Zevra Therapeutics, Inc. (ZVRA) Q2 FY26 Earnings Call

Revenue was $39.7 million, up 53% year over year, with $30.2 million from U.S. Myplifa sales.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length44 minutes
EPS$0.25
Revenue$39.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

Read the full Q2 FY26 earnings call transcript

All ZVRA earnings · Back to ZVRA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.